Web22 dic 2024 · Real‐world outcomes of pembrolizumab for platinum‐refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial‐unfit patients. International Journal of Urology. 2024-12-09 Journal article. DOI: 10.1111/iju.15101. Contributors : Katsuhiro Ito; Yuki Kita; Takashi Kobayashi. Show more detail. Web249 Background: Cisplatin-based NAC for patients (pts) with invasive BC is considered to provide a 5-8% overall survival (OS) advantage, although several studies failed to prove the survival benefit of NAC. METHODS: Eligibility criteria included histologically proven urothelial carcinoma, invasive (T2-4aN0M0) bladder cancer within 8 weeks from TURBT, …
8409 SW 102nd Ave, Gainesville, FL 32608 MLS# GC302301 Redfin
Web15 ott 2024 · Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: … WebHome / Effect of neoadjuvant chemotherapy on health-related quality of life in patients with muscle invasive bladder cancer: Results from JCOG0209, a randomized phase III study hjelmhuer
Randomized phase III trial of neoadjuvant chemotherapy (NAC) …
Web24 mar 2014 · Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: … Web7.1.1. Introduction. The standard treatment for patients with urothelial MIBC and MIBC with variant histologies is RC. However, RC only provides 5-year survival in about 50% of patients [ 246-250 ]. To improve survival in patients with cN0M0 disease, cisplatin-based NAC has been used since the 1980s [ 246-252 ]. 7.1.2. Web24 mar 2014 · Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209. hjelmin